RLMD News and Press, Relmada Therapeutics Inc. From 12/07/22

For the second time, a phase 3 trial of Relmada Therapeutics' ( NASDAQ: RLMD ) depression candidate REL-1017 has failed . Shares are down 37% in after-hours trading. Top-line results from the RELIANCE I study showed the candidate missed its primary endpoint, statistically ...

Relmada Therapeutics Announces Top-line Results from Phase 3 RELIANCE I Trial for REL-1017 as an Adjunctive Treatment for Major Depressive Disorder PR Newswire Company to Host Conference Call Today, December 7, 2022 , at 5:00 PM ET CORAL GABLES, Fla. , ...

Relmada Therapeutics, Inc. (RLMD) Q3 2022 Earnings Conference Call November 10, 2022 4:30 PM ET Company Participants Brian Ritchie - LifeSci Advisors Sergio Traversa - Chief Executive Officer Maged Shenouda - Chief Financial Officer Maurizio Fava - Chairman, ...

Relmada Therapeutics press release ( NASDAQ: RLMD ): Q3 GAAP EPS of -$1.31. As of September 30, 2022, the company had cash, cash equivalents, and short-term investments of approximately $184.2 million, compared to cash, cash equivalents, and short-term investments of appro...

Relmada Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial Results PR Newswire CORAL GABLES, Fla. , Nov. 10, 2022 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing disease...

Relmada Therapeutics to Report Third Quarter 2022 Financial Results and Host Conference Call and Webcast on November 10, 2022 PR Newswire CORAL GABLES, Fla. , Nov. 8, 2022 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnolo...

Relmada Therapeutics ( NASDAQ: RLMD ) added more than 8% into afternoon trading Monday after Point72 Asset Management, run by billionaire fund manager Steven Cohen disclosed 7.3% ownership in the clinical-stage biotech. According to a 13-G filing submitted Monday ,...

Truist and Guggenheim have downgraded Relmada Therapeutics ( NASDAQ: RLMD ) to hold and neutral, respecitvely, following the failure of phase 3 depression REL-1017 . Truist lowered its price target to $10 from $90 (~54% upside based on Thursday's close) while Guggenhei...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: ra2 studio/Shutterstock Today may be less than stellar for Relmada Therapeutics (NASDAQ: RLMD ), but it’s certainly a great day for Axsome Therapeutics (NASDAQ: AXSM ). Apparently, Relmada...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Shutterstock Relmada Therapeutics (NASDAQ: RLMD ) stock is plummeting on Thursday as investors react to results from a Phase 3 clinical trial . Unfortunately for RLMD stock, its RELIANCE III study did...